Value Investor
Start free

Zevra Therapeutics

ZVRA on Nasdaq. Zevra Therapeutics sells medicines for rare diseases to patients and doctors. Market value $635m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Recent profit includes a big one-time charge, so we price the company excluding that charge.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
5.1%fair

For every $100 of what the whole company costs, it produced $5.12 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026, without the one-off
3.9×cheap

You pay 3.9 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
-105.1%five-year median

Each dollar kept in the business earns -105 cents a year. Above 10 is good.

Quality score: 44 of 100. Price score: 95 of 100. Our list needs 70 on quality and 60 on price.

$10.73 a share, 34% above its 1-year low

Over the past year the price has ranged from $8.01 to $15.03.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.0
-0.0
-0.0
-0.1
-0.0
0.0
2021202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: $33 million in the past 12 months, a shortfall of $2 million in the year to December 2025.

Revenue
$29m$10m$27m$24m$106m
Operating margin
27.0%-418.9%-180.6%-368.5%-59.1%
Debt to equity
n/an/a0.081.500.40
Shares outstanding
0.03bn0.04bn0.05bn0.06bn0.06bn

Health checks

  • Free cash flow positive1 of 5 years
  • Accounting looks honest (Beneish)Warning signs
  • Financial strength (Piotroski)5 of 9
  • Profit backed by cash (accruals)No
  • Debt0.40× equity
  • Revenue growth, five yearsStrong, 51.6% a year
  • Buying back its own sharesNo, 72% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $40 million last quarter, up 53% on a year ago.
  • Profit: $9 million, down 88% on a year ago.
  • It keeps 61 cents of each $1 of sales as operating profit, after losing 192 cents a year earlier.
  • Spare cash over the past 12 months: $33 million. A year earlier it spent $47 million more than it brought in.
  • 9% more shares than a year ago. Each share owns a bit less of the company.
  • It has $145 million more cash than debt. A year ago debt was $13 million more than cash.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$4m
December 2024$12m
March 2025$20m
June 2025$26m
September 2025$26m
December 2025$34m
March 2026$36m
June 2026$40m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$33m
December 2024-$36m
March 2025-$3m
June 2025$75m
September 2025-$544,000
December 2025$12m
March 2026$38m
June 2026$9m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
9 March 2026
Next quarterly (estimated, 10-Q)
4 November 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 157 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 6 sold $3m, $2m of it under preset trading plans.

  • Thompson Rahsaan
    Chief Legal & Compliance
    Sold
    under a preset trading plan
    Date
    14 August 2026
    Shares
    42,666
    Price
    $11.13
    Value
    $474,774
  • Watton Corey Michael
    Director
    Sold
    Date
    10 August 2026
    Shares
    12,300
    Price
    $11.25
    Value
    $138,377
  • Thompson Rahsaan
    Chief Legal & Compliance
    Sold
    under a preset trading plan
    Date
    22 June 2026
    Shares
    34,557
    Price
    $12.68
    Value
    $438,183
  • Thompson Rahsaan
    Chief Legal & Compliance
    Sold
    under a preset trading plan
    Date
    11 May 2026
    Shares
    1,794
    Price
    $11.30
    Value
    $20,272
  • McFarlane Neil F.
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    9 February 2026
    Shares
    14,625
    Price
    $8.56
    Value
    $125,190
  • Schafer Joshua
    CCO
    Sold
    under a preset trading plan
    Date
    3 February 2026
    Shares
    10,500
    Price
    $9.19
    Value
    $96,495
  • Sangiovanni Timothy J.
    SVP, Finance & Corp Controller
    Sold
    under a preset trading plan
    Date
    3 February 2026
    Shares
    3,000
    Price
    $9.18
    Value
    $27,540
  • McFarlane Neil F.
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    2 February 2026
    Shares
    91,000
    Price
    $9.38
    Value
    $853,580
  • Schafer Joshua
    CCO
    Sold
    under a preset trading plan
    Date
    30 January 2026
    Shares
    3,375
    Price
    $8.83
    Value
    $29,801
  • Quartel Adrian W
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    30 January 2026
    Shares
    4,533
    Price
    $8.83
    Value
    $40,026

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

  • Its accounts show patterns that sometimes come before companies have to correct past results (Beneish score).
  • Profits run ahead of cash.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.